Galderma is a leading global pharmaceutical company specializing in the research, development and marketing of innovative medical solutions in dermatology. Galderma’s important investments in R&D, extensive product portfolio, global presence and expertise in three key segments (prescription drugs, therapeutic skin care and aesthetic and corrective medical solutions) contribute to maintaining its strong leadership in dermatology. Galderma is committed to delivering innovative medical solutions to meet the dermatological needs of people throughout their lifetime while serving healthcare professionals around the world. The company has 31 wholly-owned affiliates with a worldwide network of distributors and more than 4,000 employees.
Galderma Canada Inc. offers a product portfolio to treat a range of dermatological conditions including: acne, eczema, rosacea, psoriasis and non-melanoma skin cancer.
Strategic brands include:
Tactuo® and Differin® (acne), MetroGel® and Apprilon™ (rosacea), Clobex® (psoriasis), Metvix® (skin cancer), Cetaphil® (therapeutic skin care)
Gary Goodyear, Minister for Science, shares with us how the Canadian Government has taken a different approach to…